Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Neuropathy (US)

Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US (www.pipelinereview.com)
The Black Box CHF Warning for Avandia and Actos, is not new information. It merely defects the real issue-- the risk of overall cardiac events.
Luc Jasmin, MD, PhD, Attending Neurosurgeon and a Research Scientist
Cedars-Sinai Medical Center
Analysis of: Medtronic Buys Kyphon For $3.9 Billion (www.forbes.com)
Will the recent purchase of Kyphon by Medtronic signals the end of kyphoplasty? No because arcuoplasty does not restore vertebral height. Vertebroplasty, kyphoplasty and arcuoplasty essentially achieve the same goals, which brings up the question, do we need all three techniques? Arcuoplasty is the...
Analysis of: Framingham Observational Study Notes Greater Incidence Of Metabolic Syndrome Among Adults Consuming Soft Drinks (www.medicalnewstoday.com)
People, in general, who may have other concerns than their health, consume soft drinks, both regular and diet. High fructose corn syrup in our society is like lead to the Romans. Why is taking our government so long to figure this out?
Analysis of: Bristol-Myers Drug, First in New Family, Controls Blood Sugar (www.bloomberg.com)
Dapagliflozin has a long way to go to prove its efficacy and safety as a potential diabetes medication. However, innovative medications are welcome as they will be pieces of the diabetic solution puzzle.
Analysis of: Galvus(R), a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval (www.pipelinereview.com)
Galvus does not seem to have a competitive edge over Januvia, its main competition. Galvus needs to demonstrate a yet unknown significant advantage to gain significant market share.
Analysis of: Older and cheaper pills just fine for diabetes (www.reuters.com)
Long-term comparisons of glycemic control are lacking between newer and older diabetes medications. However this is a one-dimensional comparison. Newer medications have significant other advantages over the older medications, but both are needed to safely reach glycemic goals.
Jason Campagna, MD,PhD, Director of Clinical Quality and Analytics
Jason Campagna, MD,PhD, Director of Clinical Quality and Analytics
Cottage Health System
Analysis of: No Quality Benefits Seen with Electronic Health Records (www.medpagetoday.com)
The porridge of attention being lavished upon anything related to augmentation of quality and outcomes in medical practice is becoming counterproductive and is obscuring important "currents" of information. To summarize EHR's as offering no benefit is akin to saying that the iphone given to John F Kennedy's...
Analysis of: UPDATE: Novartis Wins FDA OK For Alzheimer's Drug Patch (money.cnn.com)
Alzheimer's drug patch could change quality of life of the patient and their family. Usually patients with Alzheimer's disease have more than one disease and takes three up to fifteen different medications a day. Long span release patches are very convenient to this patients for many reasons, not only...
Analysis of: UPMC draws up severe code on freebies (www.post-gazette.com)
Unilateral decisions about pharmaceutical detailing makes policy makers feel good, but the bottom line, the patients, are the ones that could pay.
Analysis of: SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes (www.pipelinereview.com)
Symlin requires a significant burden on patients without much benefit.  For the lucky few that can get away with basal insulin and Symlin and don’t mind the shots, it may be of some benefit.

Previous Page : 1 2 3 4 5 6 7 8 Next41 to 50 of 80

Analytics


Generated at 2009-01-07T19:00:58.307